Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
IPO Year: 2004
Exchange: NASDAQ
Website: inva.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2024 | Overweight | Cantor Fitzgerald | |
| 7/20/2022 | $16.00 | Neutral | Goldman |
| 2/23/2022 | $10.00 → $12.00 | Underweight | Morgan Stanley |
| 2/11/2022 | $28.00 | Buy | EF Hutton |
Cantor Fitzgerald initiated coverage of Innoviva with a rating of Overweight
Goldman initiated coverage of Innoviva with a rating of Neutral and set a new price target of $16.00
Morgan Stanley reiterated coverage of Innoviva with a rating of Underweight and set a new price target of $12.00 from $10.00 previously
EF Hutton initiated coverage of Innoviva with a rating of Buy and set a new price target of $28.00
4 - Innoviva, Inc. (0001080014) (Issuer)
4 - Innoviva, Inc. (0001080014) (Issuer)
4 - Innoviva, Inc. (0001080014) (Issuer)
4 - Innoviva, Inc. (0001080014) (Issuer)
4 - Innoviva, Inc. (0001080014) (Issuer)
4 - Innoviva, Inc. (0001080014) (Issuer)
4 - Innoviva, Inc. (0001080014) (Issuer)
4 - Innoviva, Inc. (0001080014) (Issuer)
4 - Innoviva, Inc. (0001080014) (Issuer)
3 - Innoviva, Inc. (0001080014) (Issuer)
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the UBS Global Healthcare Conference in Ranch Palos Verdes, CA on Wednesday, November 13, 2024 at 10:15 a.m. Pacific Time. A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at https://investor.inva.com/presentations-events. The webcast will b
Core royalty platform continued strong performance, receiving GSK royalties of $60.5 million with 6% year-over-year growth Innoviva Specialty Therapeutics' (IST) marketed portfolio achieved U.S. net product sales of $19.7 million, reflecting 68% year-over-year growth Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2024, and highlighted select corporate achievements. "For the
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference Format: Corporate Presentation Date: Tuesday, September 10, 2024 Time: 10:30 a.m. Eastern Time 2024 Cantor Fitzgerald Global Healthcare Conference Format: Fireside chat Date: Wednesday, September 18, 2024 Time: 3:40 p.m. Eastern Time
Core royalty platform continued strong performance, receiving GSK royalties of $67.2 million Innoviva Specialty Therapeutics' (IST) marketed portfolio grew 38% year-over-year, achieving net product sales of $21.7 million Important treatment guidelines and guidance updates recognized our key products: XACDURO® by 2024 Infectious Diseases Society of America (IDSA); XERAVA® by 2024 Surgical Infection Society XACDURO® approved in China Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strateg
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL on Monday, June 10, 2024 at 1:20 p.m. Eastern Time. A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at https://investor.inva.com/presentati
Core royalty platform on track; receiving GSK royalties of $61.9 million Achieved net product revenues of $19.1 million, representing 66% year-over-year growth driven by launch of XACDURO® and growth of key core product GIAPREZA® Strong pipeline progress: positive Phase 3 zoliflodacin clinical trial results in uncomplicated gonorrhea highlighted at ESCMID Global 2024; on track to submit NDA in early 2025 Derek Small appointed to the Company's Board of Directors Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will present at the BofA Securities Health Care Conference in Las Vegas, NV on Wednesday, May 15, 2024 at 9:20 a.m. Pacific Daylight Time. A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at https://investor.inva.com/presentations-events. The webcast
Single-dose, oral zoliflodacin achieved 90.9% microbiological cure rate, demonstrating statistical non-inferiority compared to current global standard of care Pivotal Phase 3 data to be presented by the Global Antibiotic Research & Development Partnership (GARDP) in a Scientific Sessions Oral Presentation First collaborative study between industry and a non-profit to address a World Health Organization high priority pathogen and U.S. Centers for Disease Control urgent threat Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ:INVA), today announced that positive results from the Phase 3 oral zoliflodacin trial will be highlighted in an oral presentation
Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES, March 4, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (NASDAQ:INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross proceeds to be received by the Company at closing are $35 mil
Core royalty platform on track; received GSK royalties of $69.6 million for fourth quarter Achieved net product revenues of $19.7 million for the fourth quarter of 2023 representing 35% year on year growth Strong pipeline progress in 2023: Approval and launch of first pathogen targeted antibacterial XACDURO® for treatment of HABP/VABP caused by Acinetobacter infections; positive topline Phase 3 data for oral drug zoliflodacin for treatment of uncomplicated gonorrhea Repurchased 1.1 million our common stock for $15.4 million in the fourth quarter of 2023 Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a lead
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief Financial Officer, effective August 21, 2023. "We are excited to welcome Stephen to our executive leadership team and believe the Company will benefit greatly from his background and experience," said Pavel Raifeld, Chief Executive Officer of Innoviva. "I look forward to working with Stephen to advance our strategy and create shareholder value." Mr. Basso brings more than 30 years of experience in the financial services industry and financial leadership in the pharmaceutical ind
Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned healthcare leader Dr. Deborah L. Birx as Chief Executive Officer MARINA DEL REY, Calif., July 11, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen‐specific bacteriophage therapeutics for antibiotic‐resistant and difficult‐to‐treat bacterial infections, today announced that it has entered into a credit and security agreement with Innoviva Strategic Opportunities LLC, a wholly‐owned subsidiary of Innoviva, Inc. (NASDAQ:INVA) (collectively, "Innoviva"). The gross proceeds of t
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company") and George Bickerstaff, III, Chairman of the Board of Directors of the Company (the "Board") today announced that Mr. Bickerstaff would not stand for reelection at the Company's 2023 Annual Meeting. Following the Meeting, assuming that all other members of the Board are reelected, the Board will be comprised of six members. Mr. Bickerstaff indicated that he is stepping down from the Board to focus on other professional and philanthropic pursuits, which includes his role as chair of the Board of Trustees for the International Vaccine Institute. "Serving Innoviva as Board Chairman has been an honor," said Mr. Bickerstaff. "I am v
LONDON--(BUSINESS WIRE)--Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that Jennifer Cook, David Fellows and Renée Galá have been appointed to the Gyroscope Board of Directors, effective immediately. “I am very pleased to welcome Jennifer, David, and Renée, three extremely accomplished executives with extensive biopharmaceutical backgrounds, to our board of directors,” said Khurem Farooq, Chief Executive Officer. “We look forward to their valuable contributions and unique perspectives as we continue our work to develop gene therapy beyond rare disease with the goal of delivering new medicines to people with retinal diseases.” Ms.
Cantor Fitzgerald analyst Louise Chen reiterates Innoviva (NASDAQ:INVA) with a Overweight.
Cantor Fitzgerald has initiated coverage on Innoviva, Inc. (NASDAQ:INVA), citing the company’s unique business model centered around royalties and healthcare assets. The company receives royalties from GSK plc (NYSE:GSK) for popular asthma and COPD products, including Relvar/Breo and Anoro, with combined sales of over $2 billion in 2023. “We believe their manufacturing complexity provides further protection from potential competitors,” Cantor analyst writes. Cantor projects around $1.1 billion of 5-year projected royalty revenues from GSK and initiates Innoviva with an Overweight rating. The analyst says Breo and Anoro have exceeded expectations, even during challenging times such a
Cantor Fitzgerald analyst Louise Chen initiates coverage on Innoviva (NASDAQ:INVA) with a Overweight rating.
Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, according to World Health Organization China NMPA approval based on comprehensive clinical data demonstrating robust activity of SUL-DUR against carbapenem-resistant bacterial strains In China, it is estimated there are approximately 300,000 cases of Acinetobacter infections and approximately 74% of them are carbapenem-resistant
Innoviva (NASDAQ:INVA) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.17 by 170.59 percent. This is a 9.52 percent increase over earnings of $0.42 per share from the same period last year. The company reported quarterly sales of $77.50 million which beat the analyst consensus estimate of $68.00 million by 13.97 percent. This is a 1.48 percent increase over sales of $76.37 million the same period last year.
The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued. The following stocks are considered to be notable value stocks in the healthcare sector: Organon (NYSE:OGN) - P/E: 4.4 BioNTech (NASDAQ:BNTX) - P/E: 7.47 TherapeuticsMD (NASDAQ:TXMD) - P/E: 0.52 Innoviva (NASDAQ:INVA) - P/E: 6.93 Procaps Gr (NASDAQ:PROC) - P/E: 5.84 Or
Innoviva (NASDAQ:INVA) reported quarterly earnings of $0.76 per share which beat the analyst consensus estimate of $0.23 by 230.43 percent. This is a 177.55 percent increase over losses of $(0.98) per share from the same period last year. The company reported quarterly sales of $85.84 million which beat the analyst consensus estimate of $75.51 million by 13.68 percent. This is a 30.45 percent increase over sales of $65.80 million the same period last year.
Innoviva (NASDAQ:INVA) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.27 by 262.96 percent. This is a 65 percent decrease over earnings of $2.80 per share from the same period last year. The company reported quarterly sales of $67.26 million which missed the analyst consensus estimate of $75.65 million by 11.09 percent. This is a 0 percent increase over sales of $67.26 million the same period last year.
Innoviva (NASDAQ:INVA) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.27 by 262.96 percent. This is a 65 percent decrease over earnings of $2.80 per share from the same period last year. The company reported quarterly sales of $67.26 million which missed the analyst consensus estimate of $75.65 million by 11.09 percent. This is a 0 percent increase over sales of $67.26 million the same period last year.
10-Q - Innoviva, Inc. (0001080014) (Filer)
8-K - Innoviva, Inc. (0001080014) (Filer)
10-Q - Innoviva, Inc. (0001080014) (Filer)
8-K - Innoviva, Inc. (0001080014) (Filer)
8-K - Innoviva, Inc. (0001080014) (Filer)
8-K - Innoviva, Inc. (0001080014) (Filer)
ARS - Innoviva, Inc. (0001080014) (Filer)
10-Q - Innoviva, Inc. (0001080014) (Filer)
8-K - Innoviva, Inc. (0001080014) (Filer)
DEFA14A - Innoviva, Inc. (0001080014) (Filer)
SC 13D/A - Innoviva, Inc. (0001080014) (Filed by)
SC 13G - Innoviva, Inc. (0001080014) (Subject)
SC 13D - Innoviva, Inc. (0001080014) (Subject)
SC 13D/A - Innoviva, Inc. (0001080014) (Filed by)
SC 13G/A - Innoviva, Inc. (0001080014) (Subject)
SC 13G/A - Innoviva, Inc. (0001080014) (Subject)
SC 13G/A - Innoviva, Inc. (0001080014) (Subject)
SC 13G - Innoviva, Inc. (0001080014) (Subject)
SC 13D/A - Innoviva, Inc. (0001080014) (Filed by)
SC 13D/A - Innoviva, Inc. (0001080014) (Subject)
Core royalty platform continued strong performance, receiving GSK royalties of $60.5 million with 6% year-over-year growth Innoviva Specialty Therapeutics' (IST) marketed portfolio achieved U.S. net product sales of $19.7 million, reflecting 68% year-over-year growth Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2024, and highlighted select corporate achievements. "For the
Core royalty platform continued strong performance, receiving GSK royalties of $67.2 million Innoviva Specialty Therapeutics' (IST) marketed portfolio grew 38% year-over-year, achieving net product sales of $21.7 million Important treatment guidelines and guidance updates recognized our key products: XACDURO® by 2024 Infectious Diseases Society of America (IDSA); XERAVA® by 2024 Surgical Infection Society XACDURO® approved in China Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strateg
Core royalty platform on track; receiving GSK royalties of $61.9 million Achieved net product revenues of $19.1 million, representing 66% year-over-year growth driven by launch of XACDURO® and growth of key core product GIAPREZA® Strong pipeline progress: positive Phase 3 zoliflodacin clinical trial results in uncomplicated gonorrhea highlighted at ESCMID Global 2024; on track to submit NDA in early 2025 Derek Small appointed to the Company's Board of Directors Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST
Core royalty platform on track; received GSK royalties of $69.6 million for fourth quarter Achieved net product revenues of $19.7 million for the fourth quarter of 2023 representing 35% year on year growth Strong pipeline progress in 2023: Approval and launch of first pathogen targeted antibacterial XACDURO® for treatment of HABP/VABP caused by Acinetobacter infections; positive topline Phase 3 data for oral drug zoliflodacin for treatment of uncomplicated gonorrhea Repurchased 1.1 million our common stock for $15.4 million in the fourth quarter of 2023 Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a lead
Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023 Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter Announced positive topline Phase 3 zoliflodacin data for treatment of gonorrhea in November 2023 Repurchased $11.0 million of common stock Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2023, highlighted select cor
Received GSK royalties of $65.7 million, net product revenues of $15.7 million and license revenue of $3.0 million in the second quarter of 2023 Received FDA approval for XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter Repurchased $9.2 million of common stock Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the second quarter ended June 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives
Received GSK royalties of $60.3 million, net product revenues of $11.5 million and license revenue of $8.0 million in the first quarter of 2023 Repurchased $40.3 million of common stock and paid off $96.2 million of 2023 convertible notes Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the first quarter ended March 31, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives. Gross royalty revenue from Glaxo Group Limited (GSK) for the first quarter 2023 was $60.3 million, which included royalties of
Royalties of $54.7 million in the fourth quarter of 2022 for RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® Net product sales of $14.6 million in the fourth quarter of 2022 for GIAPREZA® and XERAVA® $100 million share repurchase program initiated in the fourth quarter of 2022 Sapna Srivastava, Ph.D., appointed to the Company's Board of Directors Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the fourth quarter ended December 31, 2022. Gross royalty revenues of $54.7 million from Glaxo Group Limited ("GSK") for the fourth quarter of 2022 include
Royalties at $65.6 million in the third quarter of 2022, compared to $65.7 million in the same quarter of 2021, for RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® Announced new $100.0 million share repurchase program Completed the sale of 15% ownership interest in Theravance Respiratory Company ("TRC") to Royalty Pharma Completed acquisition of the remaining approximately 40% equity of Entasis Therapeutics Holdings Inc. ("Entasis") Completed acquisition of La Jolla Pharmaceutical Company ("La Jolla") Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results
Royalties increased by 7% to $111.7 million in the second quarter of 2022, compared to the same quarter in 2021 Completed acquisition of the remaining approximately 40% of Entasis Therapeutics at a price of $2.20 per share for a consideration of $42 million in July 2022 Entered into definitive merger agreement to acquire all outstanding shares of La Jolla Pharmaceutical Company for $6.23 per share in cash at an implied enterprise value of $149 million in July 2022 Sold 15% economic stake in Theravance Respiratory Company ("TRC") to Royalty Pharma for approximately $282 million and a potential $50 million milestone payment plus full ownership of existing equity investments TRC previou